ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 6385 participants.

Also called NCT05021835

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 6,385 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05021835
  • jRCT jRCT2021210033
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, Germany, Greece, Hungary, India, Israel, Italy, Japan, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05021835. Randomized; quadruple masking; primary purpose treatment. Start 2021-08-30 (actual); primary completion 2026-06-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
Acronym
ZEUS
Condition
Cardiovascular Risk
Condition
Inflammation
Intervention (Drug)
Ziltivekimab B
Intervention (Drug)
Ziltivekimab C
Intervention (Drug)
Placebo (Ziltivekimab B)
Intervention (Drug)
Placebo (Ziltivekimab C)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05021835
Content hash
0cea02727d86867e78bef0abc899f08aa06f3eda9fb0c36db95ac2ab51c77316